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Abstract
Background: Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and
the first drug approved for the on-demand treatment of premature ejaculation (PE). Its
safety was established in a thorough clinical development program.
Objective: To characterize the safety proﬁle of dapoxetine in PE treatment and to report
the incidence, severity, and type of adverse events.
Design, setting, and participants: We conducted a 12-wk, open-label, observational
study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled,
with 6712 patients (67.6%) treated with dapoxetine 30–60 mg (group A)and 3316
(32.4%) treated with alternative care/nondapoxetine (group B).
Interventions: Treatment with dapoxetine or alternative care/nondapoxetine.
Outcome measurements and statistical analysis: Treatment-emergent adverse events
(TEAEs) and concomitant therapy use during the 12-wk observational and the post-
observational period were reported.
Results and limitations: The mean age for all patients was 40.5 yr. In group A, 93.0% of
the patients were initially prescribed dapoxetine 30 mg. Treatment options for group B
patients included clomipramine, paroxetine, ﬂuoxetine, sertraline, topical drugs, con-
doms, and behavioral counseling. Both treatment regimens were well tolerated. TEAEs
were reported by 12.0% and 8.9% of group A and group B, respectively, with the highest
incidence observed in patients aged >65 yr for group A (21.4%) and 30–39 yr (9.8%) for
group B. Themost commonly reported TEAEswere nausea, headache, and vertigo, with a
higher incidence in group A (3.1%, 2.6%, and 1.0%, respectively) than in group B (oral
drugs: 2.3%, 1.3%, and 0.9%, respectively). There were no cases of syncope in group A and
one case in group B. A major limitation is that this was a nonrandomized, open-label,
short-term study lacking efﬁcacy data.
Conclusions: The results of this postmarketing observational study demonstrated that
dapoxetine for treatment of PE has a good safety proﬁle and low prevalence of TEAEs.
Syncope and major cardiovascular adverse events were not reported. The high level of
adherence by healthcare providers to the contraindications, special warnings, and
precautions for dapoxetine minimizes the risk for its use in routine clinical practice.
The current risk minimization measures for its identiﬁed and potential risks are
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Table 1 – Alternative care/nondapoxetine group (safety analysis
set, n = 3315)
Oral drug* No. (%)
Clomipramine 98 (6.5)
Paroxetine 629 (41.5)
Fluoxetine 27 (1.8)
Sertraline 91 (6.0)
Other 680 (44.9)
Total 1515
Other treatmenty
Topical drug 952 (32.5)
Condoms 432 (14.8)
Behavioral counseling 1182 (40.4)
Other 362 (12.4)
Total 2928
* In the alternative care/nondapoxetine group components, number counts
the patients prescribed the component at any visit. Percentages are
calculated with the total number of the alternative care/nondapoxetine oral
drug as the denominator.
y Percentages are calculated with the total number of the alternative care/
nondapoxetine other treatment as the denominator.
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Dapoxetine hydrochloride (Priligy; Janssen Pharmaceutica
NV, Beerse, Belgium), a selective serotonin reuptake inhibitor
(SSRI), was the first drug originally approved for the on-
demand treatment of premature ejaculation (PE) by seven
European countries (Austria, Finland,Germany, Italy, Portugal,
Spain, and Sweden) in 2008 [1]. Since then, it has received
marketing authorization in 59 countries worldwide.
An integrated analysis from five phase 3 trials concluded
that dapoxetine 30 mg and 60 mg significantly improved all
aspects of PE compared to placebo, including intravaginal
ejaculatory latency time, PE profile questionnaire items,
and Clinical Global Impression of Change in PE [2]. The
geometric mean fold increases were 2.5, 3.0, and 1.6 with
dapoxetine 30 mg, 60 mg, and placebo, respectively.
The safety profile of antidepressant SSRIs has never been
comprehensively studied in men with PE. It consists only of
safety data from clinical studies and spontaneously reported
adverse events in men with psychiatric disorders. Although
dapoxetine differs from other drugs within the SSRI class,
due to its rapid onset of action and elimination profile
enabling on-demand use, its mechanism of action theoreti-
cally could result in adverse events similar to other available
SSRIs. The safety assessment currently available for dapox-
etine is based ondata fromthe clinical development program
that included >6000 patients [3]. In phase 3 studies, several
well-recognized side effects of SSRIs (ie, akathisia, with-
drawal syndrome, and mood-related changes) were not
reported for dapoxetine use [2]. A low rate of vasovagal
syncope was reported in phase 3 studies, and the premar-
keting safety profile did not show evidence of serious
cardiovascular (CV) events or arrhythmias [4,5]. The primary
objectives of this studywere to characterize the safety profile
of dapoxetine when used to treat men with PE in routine
clinical practice, and to report the incidence, severity, and
typeofadverseevents (seriousadverseeventsand/oradverse
events of special clinical interest).
2. Patients and methods
2.1. Subjects
Patients with a current diagnosis of PE or who were newly diagnosed
with PE and who received therapy for this condition were enrolled in the
study. Group A included all patients treated with dapoxetine; group B
patients had alternative care/nondapoxetine treatment. The alternative
care/nondapoxetine treatment was deﬁned as any treatment other than
dapoxetine (Table 1). No speciﬁc selection criteria (inclusion or
exclusion criteria) were speciﬁed to select patients, due to the
observational nature of the study. Patients were considered for
enrollment only after the participating healthcare providers (HCPs)
had determined that either treatment with dapoxetine or alternative
care/nondapoxetine was appropriate. All patients were informed about
the observational nature of the study and gave their written consent.
2.2. Study design
This prospective, 12-wk, open-label, postmarketing observational
study was conducted at 414 sites in seven European countries(Austria, Finland, Germany, Italy, Portugal, Spain, and Sweden) with
an enrollment period ranging from September 2009 to September 2012
(ClinicalTrials.gov identiﬁer NCT01021670). The study design consisted
of three periods, as shown in Figure 1. The participating HCP prescribed
either dapoxetine or alternative care/nondapoxetine treatment after an
initial assessment of the patient during the preobservational period. The
study protocol and amendments were approved by local ethics
committees at every site, and the study was conducted in accordance
with the ethical principles of the Declaration of Helsinki and was
consistent with good clinical practice guidelines. After an initial
evaluation was performed, the participating HCP instructed the patient
to take dapoxetine in accordance with the summary of product
characteristics [6].
2.3. Outcome measures
Study-related data were collected and safety evaluations carried out to
monitor treatment-emergent adverse events (TEAEs) and concomitant
therapy use during the 12-wk observational period and at the
postobservational telephone contact. Some adverse events (ie, syncope,
mood and related, neurocognitive related, CV system, urogenital system
and sexual function, accidental injury, abnormal bleeding) were
considered of special clinical interest compared with commonly
reported TEAEs and were analyzed separately in this study. Orthostatic
vital signs (blood pressure and heart rate) were measured during the
preobservational period for patients who were dapoxetine candidates.
The ﬁrst measurement was recorded with the patient in the supine
position for at least 2 min. The second measurement was taken with the
patient in the standing or the erect position for at least 2 min following
the supine measurements but before 3 min had elapsed.
2.4. Sample size determination
The sample size was presumed to be large enough to potentially observe
at least one rare adverse event and to detect any safety issue that had not
been observed during the clinical development program. The sample size
of 6000 patients (per group) would yield a precision (half width) of
0.17%, thus constructing a 95% conﬁdence interval (CI) for an adverse
event where the adverse event rate is assumed to be 0.50% (ie, the 95% CI
would extend from 0.33% to 0.67%), which is similar to the rate of
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Fig. 1 – Study diagram.
PE = premature ejaculation.
aThe dose of dapoxetine might be modified (eg, might be increased from 30 mg to 60 mg or decreased from 60mg to 30 mg) at the discretion of the
participating healthcare provider, in accordance with the SPC.
E U RO P E AN URO L OGY 6 5 ( 2 0 1 4 ) 7 3 3 – 7 3 9 735syncope observed in phase 3 studies (0.23%) [2]. In addition, this sample
size would result in an 80% probability of observing at least one
infrequent adverse event (0.027%).
2.5. Statistical analyses
The enrolledpatient analysis set (PAS)was deﬁned as all patientswhose
information was entered into the database. All patients who took at
least one dose of dapoxetine were included in the safety analysis set
(SAS) associated with dapoxetine treatment (group A). All patients not
using dapoxetine at visit 1 and using alternative care/nondapoxetine
treatment were included in the alternative care/nondapoxetine
treatment group B. A patient was considered to have completed
the study if he ﬁnished the end-of-observation assessments. Baseline
information was described using common statistical descriptors
for continuous data, count, and percentages for categorical data. All
reported adverse events with onset during the observational period
were included in the analysis. The percentage of patients who
experienced at least one adverse event was summarized by treatment
group. We performed a multivariate logistic regression analysis for
predicting the outcome of dichotomous dependent variables, with a
statistically signiﬁcant p value set at <0.05.
3. Results
A total of 10 028 patients were included in the PAS, with
6712 patients (67.6%) selected for group A and 3316 (32.4%)
for group B. Among all the enrolled patients, 9443 (94.2%)
were included in the SAS, of whom 6128 (91.3%) and 3315
(>99.9%) belonged to groups A and B, respectively.
There were no significant differences in demographic or
baseline characteristics or in duration of the treatment
period between the two groups (Table 2). The mean age for
all patients was 40.5 yr, with most patients included in the
30- to 39-yr age group (28.0%) and the 40- to 49-yr age
group (27.0%). Most of the patients in group A were aged<65 yr and had no history of orthostatic reactions (98.1%
and >99.9%, respectively).
Evaluation for orthostatic reaction at baseline for the
dapoxetine-only treatment candidates revealed the reac-
tion in 70 patients (1.0%). Overall, 60 of the 70 patients were
included in the SAS; 6 patients took no dapoxetine, and the
remaining 4 patients underwent only a first visit. A total of
5697 patients (93.0%) were initially prescribed dapoxetine
30 mg; 431 patients (7.0%) were initially prescribed the
60-mg dose.
Most of the patients continued with the 30-mg dose at
visits 2, 3, and 4 (82.4%, 77.8%, and 76.9%, respectively)
(Table 3). An increase to the 60-mg dose occurred most
frequently at visit 2 (10.6%). For 36 (8.3%) of the 431 patients
taking 60 mg at visit 2, the dosage was decreased from
60 mg to 30 mg. Themain reason for the dose increase from
30 mg to 60 mg at visits 2, 3, and 4 (82.8%, 79.4%, and 77.9%,
respectively) was insufficient response. For most of the
patients whose dosage was decreased from 60 mg to 30 mg
at visits 2, 3, and 4 (50.0%, 47.4%, and 53.6%, respectively),
the main reason was patient preference.
The total number of dapoxetine doses per patient during
the entire study ranged from 1 to 54. Most of the patients
(61.8%) took no more than 10 doses during the treatment
period; the mean number taken during the treatment
period was 10.2. The mean duration of treatment was
similar between groups A and B (88.2 d vs 87.0 d,
respectively).
A total of 58 patients (0.9%) treated with dapoxetine
were prescribed a contraindicated concomitant therapy
during the course of the study. Antidepressants were the
most frequently used class of drugs.
A total of 540 patients (8.8%) treated with dapoxetine
used a concomitant medication with special warnings and
Table 2 – Demographics and baseline characteristics
Dapoxetine Alternative care/nondapoxetine Total
No. of patients 6712 3316 10 028
Age, yr
Mean (SD) 40.6 (11.78) 40.2 (12.35) 40.5 (11.97)
Median 40.0 39.0 40.0
Range 17–79 17–81 17–81
Race, no. (%)
White 6437 (95.9) 3189 (96.2) 9626 (96.0)
Black 79 (1.2) 41 (1.2) 120 (1.2)
Asian 62 (0.9) 51 (1.5) 113 (1.1)
Unknown 6 (0.1) 6 (0.2) 12 (0.1)
Multiple 2 (<0.1) 2 (0.1) 4 (<0.1)
Not reported 1 (<0.1) 1 (<0.1) 2 (<0.1)
Other 125 (1.9) 26 (0.8) 151 (1.5)
PE diagnosis, no. (%)
Lifelong 3133 (46.7) 1292 (39.0) 4425 (44.1)
Acquired 2951 (44.0) 1596 (48.1) 4547 (45.3)
Unsure 628 (9.4) 426 (12.8) 1054 (10.5)
Missing 0 2 (0.1) 2 (<0.1)
SD = standard deviation; PE = premature ejaculation.
For continuous variables, mean and median are rounded to one decimal point, and standard deviations are rounded to two decimal points.
Table 3 – Dose adjustments over time
Visit Dapoxetine treatment group
Total
no. (%)
Dose increase,
30 mg to 60 mg
Dose decrease,
60 mg to 30 mg
No change,
30 mg
No change,
60 mg
Visit 1* 6128 (100) 0 0 5697 (93.0) 431 (7.0)
Visit 2 5869 (95.8) 621 (10.6) 36 (0.6) 4837 (82.4) 375 (6.4)
Visit 3 5518 (90.0) 315 (5.7) 57 (1.0) 4295 (77.8) 851 (15.4)
Visit 4** 5126 (83.6) 149 (2.9) 28 (0.5) 3942 (76.9) 1006 (19.6)
* Number of patients who started with dapoxetine 30/60 mg.
** One patient receiving dapoxetine stopped at Visit 3, but dapoxetine was still prescribed at Visit 4. This patient is included in the Total column for Visit 4.
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inhibitors (PDE5-Is; 5.5%) and a-blockers (3.3%).
TEAEs were reported by 12.0% and 8.9% of patients in
groups A and B, respectively, with the highest incidence
observed in patients >65 yr of age for the dapoxetine
group (21.4%) and between 30 yr and 39 yr of age (9.8%) for
the alternative care/nondapoxetine group (Supplemental
Table 1).
The most commonly reported TEAEs (>1% in any group)
were nausea (2.4%), headache (1.9%), and vertigo (0.8%),
with a higher incidence in group A (3.1%, 2.6%, and 1.0%,
respectively) than in group B (oral drugs 2.3%, 1.3%, and
0.9%, respectively; nonoral treatments: 0.1%, 0.3%, and 0%,
respectively).
The overall number of patients experiencing at least one
TEAE was greater in patients who were titrated from the
30-mg to the 60-mg dose than in those who remained on
the 30-mg dose for the duration of the study (15.0% vs
10.9%, respectively). TEAE incidence was greater in those
who were titrated to dapoxetine 60 mg at visit 2 than in
those who remained on dapoxetine 30 mg for the duration
of the study (12.9% vs 4.8%, respectively), although for
patients remaining on dapoxetine 60 mg at visits 3 and 4,
the incidence of TEAEs was lower than at visit 2 (10.5%and 8.7%, respectively). Nausea was the most commonly
reported TEAE (Table 4) in the dapoxetine group.
A total of 22 patients included in the SAS reported severe
TEAEs during the study: 12 (0.2%) treated with dapoxetine
and 10 (0.3%) treated with alternative care/nondapoxetine;
however, none were considered related to the treatment.
No deaths were reported in either treatment group.
The incidence of patients who discontinued the study
due to a TEAE was greater in group A than in group B (1.5%
vs 0.2%, respectively), although no TEAE led to the
discontinuation of >0.3% of patients in either treatment
group (Supplemental Table 2).
Overall, the total incidence in each category of special
adverse events was low (Supplemental Table 3). The
number of patients reporting adverse events was higher
in the neurocognitive-related adverse event category (2.0%).
With the exception of the CV system (dapoxetine, 1.6%;
alternative care [oral drug], 1.3%) and accidental injury
(0.1% for both), the incidence of TEAEs of special interest in
each category was greater in group B (oral drug) than in
those treated with dapoxetine. There were no associations
between TEAEs of syncope and the orthostatic test results.
One event of syncope was reported as a serious adverse
event in a group B patient treated with paroxetine; no event
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dapoxetine.
Table 5 summarizes the independent predictor of any
grade TEAEs. Presence of CV disorders at baseline (odds ratio
[OR]: 0.619; p < 0.001), presence of metabolic disorders
at baseline (OR: 0.711; p = 0.004), alcohol assumption
(OR: 1.372; p< 0.0001), PE diagnosis (OR: 0.681; p< 0.0001),
and treatment modality (p for trend < 0.0001) were
independent predictors of TEAE, once adjusted for the other
covariates. The low number of severe TEAEs prevented us
from an analysis of predictors.
4. Discussion
The data from this postmarketing observational study
demonstrate that dapoxetine for treatment of PE has a good
safety profile and lowprevalence of TEAEs in routine clinical
practice. Key study design features that differed from
previous phase 3 studies [7–11] in the clinical development
program were a lack of strict patient-exclusion criteria (eg,
age<18 yr, comorbid erectile dysfunction, psychiatric or CV
disorders) and the ability of participating physicians to
select the starting dose of dapoxetine and adjust the dosage
during the course of the study.
An important strength of this study was the thorough
and comprehensive collection of adverse event data.
Compared with former studies, fewer patients were lost
to follow-up (6.2% vs 3.9%, respectively) and fewer patients
prematurely withdrew from the study because of the onset
of a side effect induced by the drug (approximately 31% vs
approximately 11%, respectively) [2].
The overall demographics of the enrolled population
were similar among treatment groups and to those reported
in the phase 3 study population except for a greater
proportion of men with acquired PE (44% vs 35%,
respectively). The higher prevalence of acquired PE in the
postmarketing setting may, in part, be related to the 5.5% of
patients reporting the concomitant use of a PDE5-I who
were excluded from phase 3 trials.
The overall incidence of adverse events in patients
treated with dapoxetine was lower in this study (12.0%)
compared with phase 3 studies. Most adverse events were
mild to moderate and related to the gastrointestinal or
nervous systems. Similarly, the proportion of patients who
discontinued use due to adverse events (1.5%) was lower in
this study than in the pooled phase 3 data (3.5% of
dapoxetine 30 mg and 8.8% of dapoxetine 60 mg).
Although the incidence of TEAEs in patients treated
with dapoxetine was lower than those treated with
alternative care (oral drug) (12.0% vs 16.1%, respectively),
it was greater than in those patients treated with alterna-
tive care (nonoral) treatment (3.5%). This is plausible
considering that topical and behavioral treatments are
associated with minimal and no systemic exposure,
respectively. Similarly, it is not surprising that the rate
of discontinuation due to adverse events was lower in
those patients treated with alternative care/nondapoxetine
therapies thanwith those reportedwith dapoxetine (0.2% vs
1.5%, respectively).
Table 5 – Multivariable analysis for predictors of any grade treatment-emergent adverse events
Variables OR 95% CI p value
Age, continuous 1.001 0.995–1.008 0.681
Race – – 0.416
Black vs white 1.501 0.821–2.744 0.187
Asian vs white 0.965 0.457–2.038 0.925
Presence of cardiovascular disorders (no vs yes) 0.619 0.495–0.774 <0.0001
Presence of psychiatric disorders (no vs yes) 0.566 0.304–1.053 0.072
Presence of metabolic disorders (no vs yes) 0.711 0.562–0.898 0.004
Alcohol assumption <0.0001
1–7 drinks per week vs none 1.372 1.178–1.598 <0.0001
8–14 drinks per week vs none 1.250 0.974–1.605 0.079
15 drinks per week vs none 1.508 1.054–2.159 0.025
PE diagnosis <0.0001
Acquired vs lifelong 0.681 0.585–0.793 <0.0001
Unsure vs lifelong 1.118 0.870–1.436 0.382
Treatment <0.0001
Dapoxetine vs nondapoxetine (oral) 0.750 0.629–0.894 0.001
Dapoxetine vs nondapoxetine (nonoral) 3.990 2.972–5.357 <0.0001
OR = odds ratio; CI = conﬁdence interval; PE = premature ejaculation.
E U RO P E AN URO LOG Y 6 5 ( 2 0 1 4 ) 7 3 3 – 7 3 9738Considering that adverse events among dapoxetine-
treated patients tend to be dose dependent, a greater
incidence of TEAEs in patients treated with the 60-mg dose
was expected. A trend of a lower incidence and severity of
adverse events at visit 2 on the 30-mg dose among patients
titrated to 60 mg at visit 2 compared with those who
remained on 30 mg for the duration of the study was
observed. Subsequently, adverse events were the most
frequently reported reason for a reduction from the 60-mg
to the 30-mg dose.
Among a total of 6081 subjects in the phase 3 studies, of
whom 4224 subjects were treated with dapoxetine, the
incidence of syncope was similar in patients receiving
placebo and in those treated with dapoxetine 30 mg
(0.05% vs 0.06%, respectively), although greater in subjects
treated with the 60-mg dose (0.23%) [2]. In comparison,
based on this large observational study of 6128 patients
treated with dapoxetine, it was observed that the incidence
of syncope was zero, with the upper bound of the 95%
confidence limit around 2.0 per 1000 person-years. One
syncope case (alternative care/nondapoxetine) occurred in
the context of 3315 patients (<0.1%) and was generally
consistent with the literature reports of a background rate of
vasovagal syncope of 1.31–6 per 1000 person-years [12] and
0.13% per patient [13].
The incidence of other serious adverse eventswas similar
between patients treatedwith dapoxetine and those treated
with alternative care/nondapoxetine and consistent with
the previous phase 3 studies [2].
Multivariate logistic regression analysis assessed the
variables predicting incidence of any grade TEAEs. It is
interesting to note that among predictors, CV disorders (the
absence of CV disorders at baseline decreased TEAE hazard
by 38%), metabolic disorders (the absence of metabolic
disorders at baseline decreased TEAE hazard by 29%), alcohol
assumption (>15 drinks/wk increased TEAE hazard 1.5
times), PE diagnosis (lifelong diagnosis increased TEAE
hazard by 32% related to acquired diagnosis) were found
to be statistically significant. Furthermore, dapoxetine,relative to oral alternative cares, decreased TEAE hazard by
25 times.
Finally, the results of the present study suggest the high
adherence of HCPs to the contraindications, special
warnings, and precautions for the use of dapoxetine. These
include a medical history including the presence of
orthostatic reaction and/or the use of concomitant thera-
pies that are contraindicated (antidepressants, potent
CYP3A4 inhibitor, triptans) or have precautions and
warnings when used with dapoxetine (a-blockers, moder-
ate CYP3A4 inhibitor, nitrates, PDE5inhibitors, potent
CYP2D6 inhibitors). This was confirmed by the adequate
identification of patients at risk for orthostatic reaction by
medical history evaluation and orthostatic testing, the
prescription of a 30-mg starting dose in >90% of PE
patients, and the concomitant use of drugs with special
warnings and vasodilatory properties in <10% of the
patients.
Major limitations of the study are the nonrandomized,
open-label, short-term design and the lack of efficacy data.
5. Conclusions
The results of the present postmarketing observational
study demonstrate that dapoxetine for treatment of PE has a
good safety profile, with low prevalence of TEAE. The lack of
any syncope or othermajor CV events in dapoxetine-treated
patients in this large, diverse population of men with PE
supports the positive safety and tolerability profile of
dapoxetinewhen prescribed in routine clinical practice. The
high adherence of HCPs to the contraindications, special
warnings, and precautions for the use of dapoxetine
minimizes the risk for its use.
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